APT Therapeutics has applied proprietary protein engineering strategies to produce APT102, an innovative human apyrase
therapy intended for the treatment of thrombotic diseases.
This pyrene-based sensor was used in HeLa cells to monitor the decrease in ATP levels upon addition of the ATP synthase inhibitor, oligomycin, and upon hydrolysis of ATP to ADP by apyrase
(Pak et al.
SmATPDasel, but not SmATPDase2, hydrolyses exogenous ATP and ADR Purinergic Signal.
Some secretory proteins have been described as a proteins that can modulate the immune response, these are D7 protein (37kDa), adenosine deaminase (ADA), purine hydrosilase, apyrase
(68kDa), a-glucosidase (67 kDa), 30 kDa allergen (Peng and Simons 2004).
Whether a given dispensed dNTP can be incorporated, apyrase
catalyzes the degradation of excess dNTPs via the following reaction and before the next dNTP is dispensed (12,13):
For example, apyrase
is a potent inhibitor in the tube but can potentiate thrombosis under flow due to the dynamics of local concentrations of adenosine triphosphate and adenosine diphosphate (ADP) in a concentration boundary layer (18).
Construction of an Amperometric Immunosensor using Solanum tuberosum potato Apyrase
for the Detection of Schistosomiasis
- a novel variant of bacterial acid phosphatase?